The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

According to The Business Research Company’s report, the global clinical oncology next-gen sequencing market is projected to rise from $0.39 billion in 2022 to $0.45 billion in 2023, with a 14.7% CAGR. The market size is anticipated to reach $0.75 billion in 2027, growing at a 13.7% CAGR.

What was the major driver in the clinical oncology next generation sequencing market?
The global increase in cancer cases will likely drive clinical oncology next-gen sequencing market growth. In 2021, the USA saw 1.9 million new cases and 0.6 million cancer deaths, with lung, prostate, bowel, and breast cancers being most common, comprising 43% of new cases. Consequently, the global cancer rate rise is expected to boost demand for oncology NGS market growth.

View More On The Clinical Oncology Next Generation Sequencing Market Report 2023 – https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

What was the key trend in the clinical oncology next generation sequencing market?
Companies in clinical oncology next-gen sequencing are automating workflows for precision, reduced variability. For instance, Agilent’s system enhances reaction capacity, cuts processing time, and reduces sample-to-sample variation. Sophia Genetics invests in data-driven DNA sequencing for patient diagnosis and treatment.

Which was the largest region in the clinical oncology next generation sequencing market?North America was the largest region in the clinical oncology next-generation sequencing market in 2022. Asia-Pacific was the second largest region in the global clinical oncology next-generation sequencing market share. The regions covered in the global clinical oncology next-generation sequencing market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Who are the clinical oncology next generation sequencing market prominent players?
Major players in the clinical oncology next-generation sequencing market are Thermo Fisher Scientific (Qiagen), Oxford Nanopore Technologies, QIAGEN, Myriad Genetics, Illumina, F. Hoffmann-La Roche, Perkin Elmer, Agilent Technologies, Pacific Bioscience, and Caris Life Sciences.

Key clinical oncology next generation sequencing market segments
The global clinical oncology next generation sequencing market is segmented –
1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing
2) By Application: Screening, Companion Diagnostics, Other Diagnostics
3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic laboratories

Request A Sample Of The Global Clinical Oncology Next Generation Sequencing Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=3344&type=smp

The Clinical Oncology Next Generation Sequencing Global Market Report 2023  provides a comprehensive overview on the clinical oncology next generation sequencing market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –
Oncology Molecular Diagnostics Global Market Report 2023
Next Generation Sequencing Global Market Report 2023
Molecular Diagnostics Devices And Equipment Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model